

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

10905.0003.1600

APPLICATION NO.

09/888 009

APPLICANT

FRAZER *et al.*

FILING DATE

June 11, 2001

GROUP



TECH CENTER 1600/2900

JUL 25 2002

RECEIVED

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AJ	A1	5,437,951	8/1/1995	Lowy <i>et al.</i>	435	69.1	3/16/1993
	A2	5,716,620	2/10/1998	Lowy <i>et al.</i>	424	186.1	6/7/1995
	A3	5,744,142	4/28/1998	Lowy <i>et al.</i>	424	204.1	6/7/1995
	A4	5,821,087	10/13/1998	Lowe, <i>et al.</i>	435	69.3	9/11/1996

## FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
AJ	B1	WO 93/02184	2/4/1993	PCT				
	B2	WO 96/15247	5/23/1996	PCT				
	B3	WO 96/29413	9/26/1996	PCT				
	B4	WO 96/30520	10/3/1996	PCT				
	B5	WO 98/10790	3/19/1998	PCT				
	B6	WO 98/15631	4/16/1998	PCT				
	B7	WO 98/28003	7/2/1998	PCT				
	B8	WO 98/44944	10/15/1998	PCT				
	B9	WO 99/09177	2/25/1999	PCT				
	B10	WO 99/18220	4/15/1999	PCT				
	B11	WO 00/35478	6/22/2000	PCT				

## OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

AJ	C1	Barrasso, "Treatment of genital warts: an Overview", <i>J. Obstet. Gynecol.</i> 18:S70-1(1998)
	C2	Bavinck, "HPV Infections and Immunosuppression", <i>Clin. Dermatol.</i> 15:427-37(1997)
	C3	Bernard, "Evolution of Papillomaviruses", <i>Curr. Topics Microbiol. Immunol.</i> 186:34-51(1994)
	C4	Beutner, "Therapeutic approaches to Genital Warts", <i>Am. J. Med.</i> 102:28-37(1997)
	C5	Beutner, "Imiquimod, a Patient-Applied Immune-Response Modifier for Treatment of External Genital Warts", <i>Antimicrobial Agents and Chemotherapy</i> , 42:789-794(1998)
	C6	Breitbart, "Immunization with Viruslike Particles from Cottontail Rabbit Papillomavirus (CRPV)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

A ✓

10/14/03

RECEIVED

JUL 25 2002

TECH CENTER 1600/2900

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

10905.0003.1 600

APPLICATION NO.

09/868 009


APPLICANT

FRAZER *et al.*

FILING DATE

June 11, 2001

GROUP



4)		Can Protect against Experimental CRPV Infection", <i>J. Virol.</i> 69:3959-3963(1995)
	C7	Broker, "Structure and Genetic Expression of Papillomaviruses", <i>Obstet. Gynecol Clin. N. Am.</i> 14:329-43(1987)
	C8	Carter, "The Natural History of Human Papillomavirus Type 16 Capsid Antibodies among a Cohort of University Women", <i>Infect. Dis.</i> , 174:927-36 (1996)
	C9	Coleman, "Immunological Events in Regressing Genital Warts", <i>Anat. Pathol.</i> , 102:768-73(1994)
	C10	Christensen, "Human Papillomaviruses Types 6 and 11 Have Antigenically Distinct Strongly Immunogenic Conformationally Dependent Neutralizing Epitopes", <i>Virol.</i> , 205, 329-35(1994)
	C11	Christensen, "Immunization with Viruslike Particles Induces Long-Term Protection of Rabbits against Challenge with Cottontail Rabbit Papillomavirus", <i>J. Virol.</i> 70:960-65(1996)
	C12	De Bruijn, "L1 Specific Protection from Tumor Challenge Elicited by HPV16 Virus-like Particles", <i>Virol.</i> 250:371-6(1998)
	C13	Dupuy, "Cell mediated immunity induced in mice by HPV16 L1 virus-like particles", <i>Microbial Pathogenesis</i> 22:219-25(1997)
	C14	Evander, "Identification of the $\alpha_6$ Integrin as a Candidate Receptor for Papillomavirus", <i>J. Virol.</i> 71:2449-56(1997)
	C15	Frazer, "Immunology of Papillomavirus infection", <i>Curr. Opin. Immunol.</i> 8:484-91(1996)
	C16	Giri, "Papillomavirus genomes: from sequence data to biological properties", <i>TIG</i> 2:227-32(1986)
	C17	Greenstone, "Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model", <i>Proc. Natl. Acad. Sci. USA</i> 95:1800-5(1998)
	C18	Hagenese, "Progress in the Development of HPV Vaccines", <i>Infect. Med.</i> 14:555-64(1997)
	C19	Hines, "Prospects for Human Papillomavirus vaccine development: emerging HPV vaccines", <i>Curr. Opin. Inf. Dis.</i> 11:57-61(1998)
	C20	Kimbauer, "Efficient Self-Assembly of Human Papillomavirus Type 16 L1 and L1-L2 into Virus-like Particles", <i>J. Virol.</i> 67:6929-36(1993)
	C21	Kimbauer, "Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic", <i>Proc. Natl. Acad. Sci. USA</i> 89:12180-4(1992)
	C22	Kimbauer, "Virus-like Particles of Bovine Papillomavirus Type 4 in Prophylactic and Therapeutic Immunization", <i>Virol.</i> 219:37-44(1996)
	C23	Park, "Human papillomavirus type 16 E6, E7 and L1 and type 18 proteins produced by recombinant baculovirus", <i>J. Virol. Meth.</i> 45:303-18(1993)
	C24	Peng, "Papillomavirus Virus-like Particles Can Deliver Defined CTL Epitopes to the MHC Class 1 Pathway", <i>Virol.</i> 240:147-57(1998)
✓	C25	Price, " $\alpha_6$ Integrins Are Required for Langerhans Cell Migration from the Epidermis", <i>J. Exp. Med.</i> 186:1725-35(1997)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/14/03

RECEIVED

JUL 26 2002

FBI CENTER 1600/2900

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

10905.0003.0000

APPLICATION NO.

09/868903


APPLICANT

FRAZER et al.

FILING DATE

June 11, 2001

GROUP



C26	Qi, "Epithelial Cells Display Separate Receptors for Papillomavirus VLPs and for Soluble L1 Capsid Protein", <i>Virol.</i> 216:35-45(1996)
C27	Rose, "Expression of Human Papillomavirus Type 11 L1 Protein in Insect Cells: In Vivo and In Vitro Assembly of Viruslike Particles", <i>J. Virol.</i> 67:1936-44(1993)
C28	Rose, "Serological differentiation of human papillomavirus types 11, 16, and 18 using recombinant virus-like particles", <i>J. Gen. Virol.</i> 75:2445-9(1994)
C29	Sasagawa, "Synthesis and Assembly of Virus-like Particles of Human Papillomavirus Type 6 and Type 16 in Fission Yeast <i>Schizosaccharomyces pombe</i> ", <i>Virol.</i> 206:126-35(1995)
C30	Salzman et al. "Sequence Analysis of Papillomavirus Genomes" in "The Papovaviridae: Vol. 2, the Papillomavirus" Plenum Press (1987)
C31	Schiller, "Papillomavirus-Like Particles, <i>Papillomavirus Report</i> 6:121-8(1995)
C32	Schirmbeck, "Virus-like Particles Induce MHC Class I-Restricted T Cell Responses", <i>Interviol.</i> 39:111-9(1996)
C33	Sing, "Isolation of Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes That Lyse Reed-Sternberg Cells: Implications for Immune-Mediated Therapy of EBV <sup>+</sup> Hodgkin's Disease" <i>Blood</i> 89:1978-86(1997)
C34	Sokolowski, "mRNA Instability Elements in the Human Papillomavirus Type 16 L2 Coding Region", <i>J. Virol.</i> 72:1504-15(1998)
C35	Stuart-Harris, "Clinical Applications of the Interferons", <i>Chapman and Hall Medical</i> (1997)
C36	Suzich, "Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas", <i>Proc. Natl. Acad. Sci. USA</i> 92:11553-7(1995)
C37	Walter, "Reconstruction of Cellular Immunity Against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor", <i>New England J. Med.</i> 333:1038-44(1995)
C38	Yamada, "Human Papillomavirus Type 16 Variant Lineages in United States Populations Characterized by Nucleotide Sequence Analysis of the E6, L2 and L1 Coding Segments", <i>J. Virol.</i> 69:7743-53(1995)
C39	Zhou, "Expression of Vaccinia Recombinant HPV 16 L1 and L2 ORF Proteins in Epithelial Cells Is Sufficient for Assembly of HPV Virion-like Particles", <i>Virol.</i> 251-7(1991)

10/14/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.